Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Mallinckrodt
Dow
McKesson
Colorcon

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

RYTARY Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Rytary patents expire, and when can generic versions of Rytary launch?

Rytary is a drug marketed by Impax Labs Inc and is included in one NDA. There are nine patents protecting this drug and two Paragraph IV challenges.

This drug has thirty-seven patent family members in fourteen countries.

The generic ingredient in RYTARY is carbidopa; levodopa. There are eighteen drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the carbidopa; levodopa profile page.

Drug patent expirations by year for RYTARY
Drug Prices for RYTARY

See drug prices for RYTARY

Drug Sales Revenue Trends for RYTARY

See drug sales revenues for RYTARY

Recent Litigation for RYTARY

Identify potential future generic entrants

District Court Litigation
Case NameDate
IMPAX LABORATORIES, INC. v. ZYDUS PHARMACEUTICALS USA, INC.2017-12-21
IMPAX LABORATORIES, INC. v. ACTAVIS LABORATORIES FL, INC.2015-09-17

See all RYTARY litigation

Pharmacology for RYTARY
Synonyms for RYTARY
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
500019-90-9
57308-51-7
AC1L2XHE
Carbidopa / Levodopa
CARBIDOPA AND LEVODOPA
Carbidopa Levodopa
Carbidopa mixture with Levodopa
Carbidopa-L-dopa mixt
Carbidopa-L-dopa mixt.
Carbidopa-levodopa (1:10)
Carbidopa-levodopa ER
Carbidopa-levodopa extended release
Carbidopa-levodopa mixt
Carbidopa-levodopa mixt.
carbidopa, levodopa drug combination
CHF 1512
Co-careldopa
CR-3
CR-5
DM-1992
Dopabain
Duodopa
Duopa
IPX 066
IPX066
Isicom
IVTMXOXVAHXCHI-YXLMWLKOSA-N
L-Tyrosine, 3-hydroxy-, mixt. with (S)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid
L-Tyrosine, 3-hydroxy-, mixt. with (S)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid (10:1)
Levodopa / carbidopa
levodopa carbidopa
Levodopa-carbidopa (10:1)
Levodopa/Carbidopa Solution
LS-158296
Nacom
Nakom
ND 0612
ND0612
SCHEMBL2049245
Sinemet CR
Sinemet CR4
Paragraph IV (Patent) Challenges for RYTARY
Tradename Dosage Ingredient NDA Submissiondate
RYTARY CAPSULE, EXTENDED RELEASE;ORAL carbidopa; levodopa 203312 2015-06-24
RYTARY CAPSULE, EXTENDED RELEASE;ORAL carbidopa; levodopa 203312 2015-06-10

US Patents and Regulatory Information for RYTARY

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Impax Labs Inc RYTARY carbidopa; levodopa CAPSULE, EXTENDED RELEASE;ORAL 203312-004 Jan 7, 2015 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Impax Labs Inc RYTARY carbidopa; levodopa CAPSULE, EXTENDED RELEASE;ORAL 203312-003 Jan 7, 2015 RX Yes No   Start Trial   Start Trial Y   Start Trial
Impax Labs Inc RYTARY carbidopa; levodopa CAPSULE, EXTENDED RELEASE;ORAL 203312-004 Jan 7, 2015 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Impax Labs Inc RYTARY carbidopa; levodopa CAPSULE, EXTENDED RELEASE;ORAL 203312-004 Jan 7, 2015 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Impax Labs Inc RYTARY carbidopa; levodopa CAPSULE, EXTENDED RELEASE;ORAL 203312-003 Jan 7, 2015 RX Yes No   Start Trial   Start Trial Y   Start Trial
Impax Labs Inc RYTARY carbidopa; levodopa CAPSULE, EXTENDED RELEASE;ORAL 203312-001 Jan 7, 2015 RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
AstraZeneca
McKinsey
Express Scripts
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.